Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2133-2144

  Aggarwal, Reeva ^a   Lu, Jingwei ^a   Kanji, Suman ^a   Das, Manjusri ^a   Joseph, Matthew ^a   Lustberg, Maryam B ^a   Ray, Alo ^a   Pompili, Vincent J ^a   Shapiro, Charles L ^a   Das, Hiranmoy ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

angiogenesis; apoptosis; breast cancer; cell survival; NOD SCID mice; V 2V 2 T cell; xenotransplant

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MALE; MICROVASCULATURE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CELL SURVIVAL; NOD/SCID MICE; VΓ2VΔ2 T CELL; XENOTRANSPLANT;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84882587715     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28217     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Wu Y, Mohamed H, Chillar R, et al. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 2008; 10: R3.
3. Taneja P, Maglic D, Kai F, et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 2010; 4: 15-34.
4. Morita CT, Parker CM, Brenner MB, et al. TCR usage and functional capabilities of human gamma delta T cells at birth. J Immunol 1994; 153: 3979-88.
5. Alam SM, Clark JS, Leech V, et al. T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. Immunol Lett 1992; 31: 279-83.
6. Bank I, Book M, Huszar M, et al. V delta 2+ gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors. Clin Immunol Immunopathol 1993; 67: 17-24.
7. Chargui J, Combaret V, Scaglione V, et al. Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother 2010; 33: 591-8.
8. Lu J, Aggarwal R, Kanji S, et al. Human ovarian tumor cells escape gammadelta T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS One 2011; 6: e23348.
9. Choudhary A, Davodeau F, Moreau A, et al. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol 1995; 154: 3932-40.
10. Maeurer MJ, Martin D, Walter W, et al. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996; 183: 1681-96.
11. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294: 605-9.
12. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005; 16: 590-6.
13. Gomes AQ, Martins DS, Silva-Santos B,. Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 2010; 70: 10024-7.
14. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
15. Rakoff-Nahoum S, Medzhitov R,. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9: 57-63.
16. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202: 931-9.
17. Stein M, Keshav S, Harris N, et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-92.
18. Bottazzi B, Walter S, Govoni D, et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992; 148: 1280-5.
19. Walter S, Bottazzi B, Govoni D, et al. Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic protein/JE. Int J Cancer 1991; 49: 431-5.
20. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
21. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926-35.
22. Samuel S, Fan F, Dang LH, et al. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 2011; 30: 1205-12.
23. Das H, Groh V, Kuijl C, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83-93.
24. Das H, Sugita M, Brenner MB,. Mechanisms of Vdelta1 gammadelta T cell activation by microbial components. J Immunol 2004; 172: 6578-86.
25. Das H, Wang L, Kamath A, et al. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001; 98: 1616-8.
26. Das H, George JC, Joseph M, et al. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One 2009; 4: e7325.
27. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
28. Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-84.
29. Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63: 8996-9006.
30. Vanky F, Wang P, Patarroyo M, et al. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 1990; 31: 19-27.
31. Schwaeble W, Kerlin M, Meyer zum Buschenfelde KH, et al. De novo expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in pancreas cancer. Int J Cancer 1993; 53: 328-33.
32. Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269-83.
33. Vogelstein B, Lane D, Levine AJ,. Surfing the p53 network. Nature 2000; 408: 307-10.
34. Sykes SM, Mellert HS, Holbert MA, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006; 24: 841-51.
35. Loibl S, Strank C, von Minckwitz G, et al. Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast 2005; 14: 230-5.
36. Brown CE, Vishwanath RP, Aguilar B, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007; 179: 3332-41.
37. Dehqanzada ZA, Storrer CE, Hueman MT, et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006; 12: 478-86.
38. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282-9.
39. Valkovic T, Fuckar D, Stifter S, et al. Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma. J Cancer Res Clin Oncol 2005; 131: 453-8.
40. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265-70.
41. Pupa SM, Bufalino R, Invernizzi AM, et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996; 14: 85-94.
42. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
43. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005; 6: 928-37.
44. Zachary I,. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003; 31: 1171-7.
45. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-43.
46. Salcedo R, Ponce ML, Young HA, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
47. Valkovic T, Lucin K, Krstulja M, et al. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 1998; 194: 335-40.
48. Bissell MJ, Hines WC,. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-9.
49. No M, Choi EJ, Kim IA,. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther 2009; 8: 2351-61.
50. Shapiro CL, Recht A,. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.